HERO: Relugolix versus leuprolide acetate for advanced prostate cancer

Bookmark and Share
Published: 10 Jul 2020
Views: 150
Dr Neal Shore - Carolina Urologic Research Center, South Carolina, USA

Prof Neal Shore speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.

He gives an overview of the HERO phase III trial, which compared the safety and efficacy of relugolix (an oral GnRH receptor antagonist) with leuprolide acetate in advanced prostate cancer patients.

Prof Shore explains the encouraging results of this study, which supports the potential role of relugolix as the new standard for testosterone suppression in this patient population.